PD‑L1 by IHC, Tecentriq®
Also known as: VENTANA® PD-L1 (SP142) Assay
Use
This is a qualitative immunohistochemistry (IHC) assay (clone SP142) intended for the detection of PD‑L1 expression in formalin‑fixed, paraffin‑embedded (FFPE) tumor tissue from non‑small‑cell lung cancer (NSCLC) and triple‑negative breast cancer (TNBC). PD‑L1 expression may guide therapeutic selection, particularly for Tecentriq® (atezolizumab) treatment.
Special Instructions
Requires FFPE tissue blocks or unstained slides. Recommended fixation: 10% neutral buffered formalin with a minimum of 6 hours fixation time; other fixatives are not recommended.
Limitations
Fixation less than 6 hours may significantly reduce staining intensity. Unsuitable specimens (e.g., cytology samples) may be rejected. Cases of insufficient tissue or incorrect specimen type are not accepted.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One FFPE tissue block or four unstained positively charged slides (4–5 µm), sectioned from FFPE block less than 2 months after sectioning
Minimum Volume
Not provided
Container
Tissue block or slides
Collection Instructions
Fixed in 10% neutral buffered formalin for at least 6 hours
Storage Instructions
Room temperature
Causes for Rejection
Insufficient tissue; inappropriate tissue source; incorrect specimen type; cytology samples not accepted